Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

RECOURSE trial: Performance status at discontinuation in patients receiving trifluridine/tipiracil (TAS-102)

Date

08 Oct 2016

Session

Poster Display

Presenters

Eric Van Cutsem

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

E. Van Cutsem1, R. Garcia-Carbonero2, A. Pastorino3, A. Zaniboni4, A. Falcone5, N. Amellal6, F. Benedetti7, R. Mayer8, A. Ohtsu9, J. Tabernero10

Author affiliations

  • 1 Digestive Oncology, University Hospitals Leuven - Campus Gasthuisberg, 3000 - Leuven/BE
  • 2 Oncology, University Hospital 12 De Octubre, Madrid/ES
  • 3 Department Of Medical Oncology, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, 1632 - Genova/IT
  • 4 Oncology, Fondazione Poliambulanza, Brescia/IT
  • 5 Dept. Of Oncology-presidio Ospedaliero, Azienda Ospedaliera Universitaria S.Chiara, 56100 - Pisa/IT
  • 6 92284, Institut de Recherches Internationales SERVIER (I.R.I.S.), SURESNES/FR
  • 7 Oncology, Taiho, Tokyo/JP
  • 8 Gastrointestinal Cancer, Dana-Farber Cancer Institute, Boston/US
  • 9 Department Of Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 10 Oncologia Médica, Vall d`Hebron University Hospital Institut d'Oncologia, 08035 - Barcelona/ES
More

Resources

Background

The efficacy and safety of trifluridine/tipiracil (TAS-102) has been explored in patients with metastatic colorectal cancer (mCRC) refractory who were intolerant to standard therapies in the phase 3 RECOURSE trial. Treatment with trifluridine/tipiracil was associated with significantly improved overall and progression-free survival versus placebo. In a post hoc analysis, we compared the level of performance status (PS) at treatment discontinuation in the two arms.

Methods

PS was evaluated in RECOURSE using the Eastern Cooperative Oncology Group (ECOG) score. Patients included in this trial had PS = 0 or 1 at baseline. The PS at treatment discontinuation with ECOG scores 0 to 4 was compared to PS at baseline on treatment and placebo (descriptive statistics).

Results

A total of 759 patients (95% of the RECOURSE population) had information on PS at treatment discontinuation. Of these, 424 (53%) had PS = 0 and 335 (42%) had PS = 1. Of the 496 trifluridine/tipiracil patients who discontinued treatment, 340 (69%) maintained the same level of PS, and only 78 (16%) had PS ≥ 2 at discontinuation (Table). Similar values were found in placebo patients, with 170/263 (65%) maintaining their PS and 50/263 (19%) with PS ≥ 2 at discontinuation.

Baseline PS
Trifluridine/tipiracil Placebo
0 (n = 278) 1 (n = 218) 0 (n = 146) 1 (n = 117)
PS at discontinuation
0 180 (65%) 8 (4%) 86 (60%) 4 (3%)
1 78 (28%) 152 (70%) 43 (30%) 80 (68%)
2 13 (5%) 40 (18%) 13 (9%) 22 (19%)
3 6 (2%) 17 (8%) 4 (3%) 8 (7%)
4 1 (0.4%) 1 (0.5%) 0 3 (3%)

Conclusions

Our results indicate that, despite expected treatment-related adverse events, the level of PS at treatment progression was maintained in patients treated with trifluridine/tipiracil.

Clinical trial identification

Legal entity responsible for the study

Taiho and Institut de Recherches Internationales Servier

Funding

Taiho and Institut de Recherches Internationales Servier

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings